Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén & Peter Ellmark. (2021) Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy 21:12, pages 1635-1646.
Read now
Read now
Alistair M. Cook, Alison M. McDonnell, Richard A. Lake & Anna K. Nowak. (2016) Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. OncoImmunology 5:3.
Read now
Read now
Scott M.J. Cornwall, Matthew Wikstrom, Arthur W. Musk, John Alvarez, Anna K. Nowak & Delia J. Nelson. (2016) Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. OncoImmunology 5:2.
Read now
Read now
Zuoan Yi & Gail A Bishop. (2015) Regulatory role of CD40 in obesity-induced insulin resistance. Adipocyte 4:1, pages 65-69.
Read now
Read now
Articles from other publishers (54)
Carlos O. Ontiveros, Clare E. Murray, Grace Crossland & Tyler J. Curiel. (2023) Considerations and Approaches for Cancer Immunotherapy in the Aging Host. Cancer Immunology Research 11:11, pages 1449-1461.
Crossref
Crossref
Ondrej Uher, Katerina Hadrava Vanova, Radka Lencova, Andrea Frejlachova, Herui Wang, Zhengping Zhuang, Jan Zenka & Karel Pacak. (2023) Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy. Frontiers in Endocrinology 14.
Crossref
Crossref
Fei Gao, Jianjun Han, Li Jia, Jun He, Yun Wang, Mi Chen, Xiaojun Liu & Xia He. (2022) MiR-30c facilitates natural killer cell cytotoxicity to lung cancer through targeting GALNT7. Genes & Genomics 45:2, pages 247-260.
Crossref
Crossref
Bruce W.S. Robinson, Alec J. Redwood & Jenette Creaney. (2022) How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies. Frontiers in Pharmacology 13.
Crossref
Crossref
Yue Du & Jian Xu. (2021) Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials 33:48, pages 2103114.
Crossref
Crossref
Madhu S. Pandey, Chunlei Wang, Scott Umlauf & Shihua Lin. (2021) Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells. International Journal of Molecular Sciences 22:21, pages 11302.
Crossref
Crossref
Ondrej Uher, Thanh-Truc Huynh, Boqun Zhu, Lucas A. Horn, Veronika Caisova, Katerina Hadrava Vanova, Rogelio Medina, Herui Wang, Claudia Palena, Jindrich Chmelar, Zhengping Zhuang, Jan Zenka & Karel Pacak. (2021) Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. Cancers 13:16, pages 3942.
Crossref
Crossref
Erin L. Filbert, Pia K. Björck, Minu K. Srivastava, Frances R. Bahjat & Xiaodong Yang. (2021) APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunology, Immunotherapy 70:7, pages 1853-1865.
Crossref
Crossref
Jean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, Dmitriy Zamarin, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Wolfgang Jacob, Anna-Maria Jegg, Michael A Cannarile, Carl Watson, Galina Babitzki, Konstanty Korski, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Francesca Michielin, Randolph Christen, Dominik Rüttinger, Martin Weisser, Jean-Pierre Delord & Philippe Cassier. (2020) Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. Journal for ImmunoTherapy of Cancer 8:2, pages e001153.
Crossref
Crossref
Robert H. Vonderheide. (2020) CD40 Agonist Antibodies in Cancer Immunotherapy. Annual Review of Medicine 71:1, pages 47-58.
Crossref
Crossref
Tamas Fulop, Jacek M. Witkowski, K. Hirokawa, A. Larbi & G. Pawelec. 2020. Geriatric Oncology. Geriatric Oncology
71
90
.
Shiming Ye, Diane Cohen, Nicole A. Belmar, Donghee Choi, Siu Sze Tan, Mien Sho, Yoshiko Akamatsu, Han Kim, Ramesh Iyer, Jean Cabel, Marc Lake, Danying Song, John Harlan, Catherine Zhang, Yuni Fang, Alan F. Wahl, Patricia Culp, Diane Hollenbaugh & Debra T. Chao. (2019) A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity. Cancer Immunology Research 7:11, pages 1864-1875.
Crossref
Crossref
Sandra M. M. Irenaeus, Dorte Nielsen, Peter Ellmark, Jeffrey Yachnin, Adnan Deronic, Anneli Nilsson, Per Norlén, Niina Veitonmäki, Camilla S. Wennersten & Gustav J. Ullenhag. (2019) First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies. International Journal of Cancer 145:5, pages 1189-1199.
Crossref
Crossref
Ondrej Uher, Veronika Caisova, Per Hansen, Jan Kopecky, Jindrich Chmelar, Zhengping Zhuang, Jan Zenka & Karel Pacak. (2019) Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Seminars in Oncology 46:4-5, pages 385-392.
Crossref
Crossref
Maja Zabel, Peter A. Tauber & Winfried F. Pickl. (2019) The making and function of CAR cells. Immunology Letters 212, pages 53-69.
Crossref
Crossref
Jian Li, Xiao-Hong Zhang, Song-Hua Bei & Li Feng. (2019) PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives. World Journal of Meta-Analysis 7:3, pages 101-109.
Crossref
Crossref
Paola Bonaventura, Tala Shekarian, Vincent Alcazer, Jenny Valladeau-Guilemond, Sandrine Valsesia-Wittmann, Sebastian Amigorena, Christophe Caux & Stéphane Depil. (2019) Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Christine N. VuongWen-Ko ChouWhitney BriggsOlivia FaulknerAmanda WolfendenMelina JonasDarrell R. KapczynskiBilly M. HargisLisa R. BielkeLuc R. Berghman. (2018)
Crude Inactivated Influenza A Virus Adjuvated with a Bispecific Antibody Complex Targeting Chicken CD40 and AIV M2e Confers Protection Against Lethal
HPA
I Challenge in Chickens
. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 37:6, pages 245-251.
Crossref
Crossref
Marta Compte, Seandean Lykke Harwood, Ines G. Muñoz, Rocio Navarro, Manuela Zonca, Gema Perez-Chacon, Ainhoa Erce-Llamazares, Nekane Merino, Antonio Tapia-Galisteo, Angel M. Cuesta, Kasper Mikkelsen, Eduardo Caleiras, Natalia Nuñez-Prado, M. Angela Aznar, Simon Lykkemark, Jorge Martínez-Torrecuadrada, Ignacio Melero, Francisco J. Blanco, Jorge Bernardino de la Serna, Juan M. Zapata, Laura Sanz & Luis Alvarez-Vallina. (2018) A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nature Communications 9:1.
Crossref
Crossref
Vincent Hurez, Álvaro Padrón, Robert S. Svatek & Tyler J. Curiel. (2018) Considerations for successful cancer immunotherapy in aged hosts. Experimental Gerontology 107, pages 27-36.
Crossref
Crossref
Joanne K. Gardner, Scott M. J. Cornwall, Arthur W. Musk, John Alvarez, Cyril D. S. Mamotte, Connie Jackaman, Anna K. Nowak & Delia J. Nelson. (2018) Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation. PLOS ONE 13:4, pages e0195313.
Crossref
Crossref
Eva Dahlén, Niina Veitonmäki & Per Norlén. (2018) Bispecific antibodies in cancer immunotherapy. Therapeutic Advances in Vaccines and Immunotherapy 6:1, pages 3-17.
Crossref
Crossref
Jean-Baptiste Gorin, Jérémie Ménager, Yannick Guilloux, Jean-François Chatal, Joëlle Gaschet & Michel Chérel. 2018. Resistance to Ibritumomab in Lymphoma. Resistance to Ibritumomab in Lymphoma
119
137
.
Tamas Fulop, J. M. Witkowski, K. Hirokawa, A. Larbi & G. Pawelec. 2018. Geriatric Oncology. Geriatric Oncology
1
20
.
Alison M. McDonnell, Alistair Cook, Bruce W. S. Robinson, Richard A. Lake & Anna K. Nowak. (2017) Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. BMC Cancer 17:1.
Crossref
Crossref
Sophie Doublier, Cristina Zennaro, Luca Musante, Tiziana Spatola, Giovanni Candiano, Maurizio Bruschi, Luca Besso, Massimo Cedrino, Michele Carraro, Gian Marco Ghiggeri, Giovanni Camussi & Enrico Lupia. (2017) Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS. PLOS ONE 12:11, pages e0188045.
Crossref
Crossref
Janneke E. Jaspers & Renier J. Brentjens. (2017) Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacology & Therapeutics 178, pages 83-91.
Crossref
Crossref
Donye Dominguez, Cong Ye, Zhe Geng, Siqi Chen, Jie Fan, Lei Qin, Alan Long, Long Wang, Zhuoli Zhang, Yi Zhang, Deyu Fang, Timothy M. Kuzel & Bin Zhang. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. The Journal of Immunology 198:3, pages 1365-1375.
Crossref
Crossref
Marta Garnelo, Alex Tan, Zhisheng Her, Joe Yeong, Chun Jye Lim, Jinmiao Chen, Kiat Hon Lim, Achim Weber, Pierce Chow, Alexander Chung, London Lucien PJ Ooi, Han Chong Toh, Mathias Heikenwalder, Irene O L Ng, Alessandra Nardin, Qingfeng Chen, Jean-Pierre Abastado & Valerie Chew. (2017) Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 66:2, pages 342-351.
Crossref
Crossref
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017.
289
383
.
Yao Hao, Sayeda Yasmin-Karim, Michele Moreau, Neeharika Sinha, Erno Sajo & Wilfred Ngwa. (2016)
Enhancing radiotherapy for lung cancer using immunoadjuvants delivered
in situ
from new design radiotherapy biomaterials: a preclinical study
. Physics in Medicine and Biology 61:24, pages N697-N707.
Crossref
Crossref
V Hurez, Á S Padrón, R S Svatek & T J Curiel. (2017) Considerations for successful cancer immunotherapy in aged hosts. Clinical and Experimental Immunology 187:1, pages 53-63.
Crossref
Crossref
Marie de Charette, Aurélien Marabelle & Roch Houot. (2016) Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. European Journal of Cancer 68, pages 134-147.
Crossref
Crossref
Antonius Steven, Scott A. Fisher & Bruce W. Robinson. (2016) Immunotherapy for lung cancer. Respirology 21:5, pages 821-833.
Crossref
Crossref
Oladapo O. YekuRenier J. Brentjens. (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochemical Society Transactions 44:2, pages 412-418.
Crossref
Crossref
Jonathan E. Schoenhals, Steven N. Seyedin, Chad Tang, Maria A. Cortez, Sharareh Niknam, Efrosini Tsouko, Joe Y. Chang, Stephen M. Hahn & James W. Welsh. (2016) Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy. The Cancer Journal 22:2, pages 130-137.
Crossref
Crossref
Manzoor M KhanManzoor M. Khan. 2016. Immunopharmacology. Immunopharmacology
397
425
.
Farhad Fakhrejahani, Yusuke Tomita, Agnes Maj-Hes, Jane B. Trepel, Maria De Santis & Andrea B. Apolo. (2015) Immunotherapies for bladder cancer. Current Opinion in Urology 25:6, pages 586-596.
Crossref
Crossref
Kevin J Curran, Beatrijs A Seinstra, Yan Nikhamin, Raymond Yeh, Yelena Usachenko, Dayenne G van Leeuwen, Terence Purdon, Hollie J Pegram & Renier J Brentjens. (2015) Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression. Molecular Therapy 23:4, pages 769-778.
Crossref
Crossref
Sara M. Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tötterman & Peter Ellmark. (2015) The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity. Clinical Cancer Research 21:5, pages 1115-1126.
Crossref
Crossref
Eugene M. Cozza, Timothy K. Cooper, Lynn R. Budgeon, Neil D. Christensen & Todd D. Schell. (2014) Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunology, Immunotherapy 64:3, pages 325-336.
Crossref
Crossref
Kim L Brunekreeft, Corinna Strohm, Marloes J Gooden, Anna A Rybczynska, Hans W Nijman, Götz U Grigoleit, Wijnand Helfrich, Edwin Bremer, Daniela Siegmund, Harald Wajant & Marco de Bruyn. (2014) Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Molecular Cancer 13:1.
Crossref
Crossref
Andrea Khong, Amanda L Cleaver, Muhammad Fahmi Alatas, Ben C Wylie, Theresa Connor, Scott A Fisher, Steve Broomfield, Willem J Lesterhuis, Andrew J Currie, Richard A Lake & Bruce W Robinson. (2014) The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer 14:1.
Crossref
Crossref
Wei Xu, Yuanyuan Xu, Yunyan Wei, Yaoxi Tan, Hongye Zhao, Weihong Zhao & Jianqing Wu. (2014) Self‑complementary adeno‑associated virus�5‑mediated gene transduction of a novel CD40L mutant confers direct antitumor effects in lung carcinoma. Molecular Medicine Reports.
Crossref
Crossref
Jennifer A. Westwood, Geoffrey M. Matthews, Jake Shortt, David Faulkner, Hollie J. Pegram, Connie P.M. Duong, Marta Chesi, P. Leif Bergsagel, Leslie L. Sharp, Richard D. Huhn, Phillip K. Darcy, Ricky W. Johnstone & Michael H. Kershaw. (2014) Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research 38:8, pages 948-954.
Crossref
Crossref
Connie Jackaman & Delia J. Nelson. (2014) Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?. Experimental Gerontology 54, pages 53-57.
Crossref
Crossref
Bianca von Scheidt, Patrick S.K. Leung, Michelle C.R. Yong, Yu Zhang, Jennifer E. Towne, Mark J. Smyth & Michele W.L. Teng. (2014) Combined Anti-CD40 and Anti–IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases. Cancer Research 74:9, pages 2412-2421.
Crossref
Crossref
Ruey-Shyang Soong, Liwen Song, Janson Trieu, Sung Yong Lee, Liangmei He, Ya-Chea Tsai, T.-C. Wu & Chien-Fu Hung. (2014) Direct T Cell Activation via CD40 Ligand Generates High Avidity CD8+ T Cells Capable of Breaking Immunological Tolerance for the Control of Tumors. PLoS ONE 9:3, pages e93162.
Crossref
Crossref
Xiaoyi Qu, Mildred A.R. Felder, Zulmarie Perez Horta, Paul M. Sondel & Alexander L. Rakhmilevich. (2013) Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. International Immunopharmacology 17:4, pages 1141-1147.
Crossref
Crossref
Zhi-Qing Wang, Jun Wang, Wei-Hua Ling, Xue-Guang Zhang & Qin Shi. (2013) Effects of CD40 ligation combined with chemotherapy drugs on human breast cancer cell lines. Journal of International Medical Research 41:5, pages 1495-1504.
Crossref
Crossref
Shi-Yong Sun. (2013) mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters 340:1, pages 1-8.
Crossref
Crossref
Edwin Bremer. (2013) Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. ISRN Oncology 2013, pages 1-25.
Crossref
Crossref
Timothy Kayes, Yujiang Fang, Shiguang Yu, Edward Downey, Shufang Wang & Helen Braley-Mullen. (2013) Agonistic Anti-CD40 Induces Thyrocyte Proliferation and Promotes Thyroid Autoimmunity by Increasing CD40 Expression on Thyroid Epithelial Cells. The Journal of Immunology 190:8, pages 3928-3938.
Crossref
Crossref
Ramon Arens, Thorbald van Hall, Sjoerd H. van der Burg, Ferry Ossendorp & Cornelis J.M. Melief. (2013) Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Seminars in Immunology 25:2, pages 182-190.
Crossref
Crossref